Literature DB >> 7983770

Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells.

H Fang1, S H Pincus.   

Abstract

To study the variability of human immunodeficiency virus type 1 (HIV-1), we used immunotoxins to select for variants within a population of H9 cells persistently infected with a molecular clone of HIV-1 designated NL4-3. Chimeric immunotoxin CD4-PE40 (a chimeric fusion protein consisting of the amino-terminal two domains of CD4 and the carboxy-terminal domains of Pseudomonas exotoxin A) was used to select for cells lacking cell surface expression of HIV Env (envelope proteins gp160, gp120, and gp41). The cells described here (A1, A7, C9, and E9) fail to express HIV proteins because they have markedly diminished transcription of the integrated provirus (A1, A7, and E9) or no HIV provirus (C9). Analysis demonstrated that two different cloned variants, A1 and E9, contain the complementary sequence of tRNA(3Lys) (45 bp) inserted 3' to the primer-binding site, following by a 169-bp deletion through the start of the gag gene. No HIV mRNA was detected by Northern (RNA) blotting, but PCR demonstrated the presence of the viral message. These variants were found very infrequently in the unselected H9/NL4-3 cell population, and they contained proviruses distinct from that found in the dominant population. In addition, all of these variants had similar patterns of CD4 surface expression that allowed them to escape reinfection within the tissue culture. The data are discussed with regard to mechanisms and errors of HIV reverse transcription, as well as the evolution of mutants within a population of persistently infected cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7983770      PMCID: PMC188550          DOI: 10.1128/JVI.69.1.75-81.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy.

Authors:  S H Pincus; K Wehrly
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule.

Authors:  D E McCallus; K E Ugen; A I Sato; W V Williams; D B Weiner
Journal:  Viral Immunol       Date:  1992       Impact factor: 2.257

3.  Characterization of large deletions occurring during a single round of retrovirus vector replication: novel deletion mechanism involving errors in strand transfer.

Authors:  G A Pulsinelli; H M Temin
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

4.  In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.

Authors:  S H Pincus; R L Cole; E M Hersh; D Lake; Y Masuho; P J Durda; J McClure
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

5.  Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

Authors:  M A Till; S Zolla-Pazner; M K Gorny; J S Patton; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Authors:  V K Chaudhary; T Mizukami; T R Fuerst; D J FitzGerald; B Moss; I Pastan; E A Berger
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

7.  Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients.

Authors:  B Chesebro; K Wehrly; J Metcalf; D E Griffin
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

8.  Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1.

Authors:  Y W Kim; M S Fung; N C Sun; C R Sun; N T Chang; T W Chang
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

9.  CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.

Authors:  E A Berger; K A Clouse; V K Chaudhary; S Chakrabarti; D J FitzGerald; I Pastan; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.

Authors:  S H Pincus; K Wehrly; E Tschachler; S F Hayes; R S Buller; M Reitz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  3 in total

1.  Evidence for the acquisition of multi-drug resistance in an HIV-1 clinical isolate via human sequence transduction.

Authors:  Yutaka Takebe; Alice Telesnitsky
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

2.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Authors:  Paul W Denton; Julie M Long; Stephen W Wietgrefe; Craig Sykes; Rae Ann Spagnuolo; Olivia D Snyder; Katherine Perkey; Nancie M Archin; Shailesh K Choudhary; Kuo Yang; Michael G Hudgens; Ira Pastan; Ashley T Haase; Angela D Kashuba; Edward A Berger; David M Margolis; J Victor Garcia
Journal:  PLoS Pathog       Date:  2014-01-09       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.